111 related articles for article (PubMed ID: 29927772)
21. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
Zhong A; Xiong X; Shi M; Xu H
Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
[TBL] [Abstract][Full Text] [Related]
22. Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed.
Assayag M; Rouvier P; Gauthier M; Costel G; Cluzel P; Mercadal L; Deray G; Isnard Bagnis C
BMC Cancer; 2017 Nov; 17(1):770. PubMed ID: 29145816
[TBL] [Abstract][Full Text] [Related]
23. Inflamed Actinic Keratoses After Pemetrexed.
Cameron MC; Suárez AL; Kris MG; Myskowski PL
Skinmed; 2016; 14(6):473-474. PubMed ID: 28031141
[TBL] [Abstract][Full Text] [Related]
24. Image of the month. Rash in a patient treated with pemetrexed for relapsed non-small cell lung cancer.
Declercq I; Lievens Y; Verbeken E; Vansteenkiste J
J Thorac Oncol; 2008 Jun; 3(6):662-3. PubMed ID: 18520810
[No Abstract] [Full Text] [Related]
25. [Pemetrexed for Treatment of Nonsquamous Non-Small-Cell Lung Cancer].
Omori Y; Enatsu S
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1609-1613. PubMed ID: 30449848
[TBL] [Abstract][Full Text] [Related]
26. Pemetrexed-induced scleroderma-like conditions in the lower legs of a patient with non-small cell lung carcinoma.
Ishikawa K; Sakai T; Saito-Shono T; Miyawaki M; Osoegawa A; Sugio K; Ono A; Mori H; Nishida H; Yokoyama S; Okamoto O; Fujiwara S; Hatano Y
J Dermatol; 2016 Sep; 43(9):1071-4. PubMed ID: 26992088
[TBL] [Abstract][Full Text] [Related]
27. Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer.
Miyahara T; Sueoka-Aragane N; Iwanaga K; Ureshino N; Komiya K; Nakamura T; Nakashima C; Abe T; Matsunaga H; Kimura S
Med Oncol; 2017 Nov; 34(12):195. PubMed ID: 29124473
[TBL] [Abstract][Full Text] [Related]
28. [Role of pemetrexed in the treatment of advanced non-small-cell lung cancer: news from ASCO, 2008].
de Marinis F; Ricciardi S
Tumori; 2008; 94(5):suppl 3-13. PubMed ID: 19112963
[No Abstract] [Full Text] [Related]
29. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M
J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654
[TBL] [Abstract][Full Text] [Related]
30. Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer.
de Marinis F; Passaro A; Clarke S
Lung Cancer; 2013 Dec; 82(3):511. PubMed ID: 24080011
[No Abstract] [Full Text] [Related]
31. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
[TBL] [Abstract][Full Text] [Related]
32. Pemetrexed-induced lower limb pseudocellulitis.
Liau MM; Santosa A; Huang J; Tan LC
Clin Exp Dermatol; 2017 Dec; 42(8):914-916. PubMed ID: 28815694
[No Abstract] [Full Text] [Related]
33. The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer.
Kim YS; Sun JM; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2013 Aug; 81(2):231-5. PubMed ID: 23683535
[TBL] [Abstract][Full Text] [Related]
34. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
35. Enhanced treatment of lung cancer by metronomic therapy with oral pemetrexed.
Park K
J Control Release; 2018 Aug; 284():250-251. PubMed ID: 30097256
[No Abstract] [Full Text] [Related]
36. Pemetrexed-induced typhlitis in non-small cell lung cancer.
Shvartsbeyn M; Edelman MJ
J Thorac Oncol; 2008 Oct; 3(10):1188-90. PubMed ID: 18827618
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
Koba T; Minami S; Nishijima-Futami Y; Masuhiro K; Kimura H; Futami S; Yaga M; Mori M; Kagawa H; Uenami T; Kohmo S; Otsuka T; Yamamoto S; Komuta K; Kijima T
Cancer Chemother Pharmacol; 2018 Jul; 82(1):111-117. PubMed ID: 29728800
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
Yoshimura N; Kudoh S; Mitsuoka S; Yoshimoto N; Oka T; Nakai T; Suzumira T; Matusura K; Tochino Y; Asai K; Kimura T; Kawaguchi T; Hirata K
Lung Cancer; 2015 Oct; 90(1):65-70. PubMed ID: 26238424
[TBL] [Abstract][Full Text] [Related]
39. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
Ciuleanu T; Brodowicz T; Zielinski C; Kim JH; Krzakowski M; Laack E; Wu YL; Bover I; Begbie S; Tzekova V; Cucevic B; Pereira JR; Yang SH; Madhavan J; Sugarman KP; Peterson P; John WJ; Krejcy K; Belani CP
Lancet; 2009 Oct; 374(9699):1432-40. PubMed ID: 19767093
[TBL] [Abstract][Full Text] [Related]
40. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
